Navigation Links
EvaluatePharma Appoints Alexander Karle as COO
Date:9/12/2012

LONDON and BOSTON, September 12, 2012 /PRNewswire/ --

EvaluatePharma®, the premier source for life science sector analysis and consensus forecasts, has appointed Alexander Karle as Chief Operating Officer. Karle's experience in formulating customer-centric growth strategies and leading them to successful implementation will be instrumental in driving EvaluatePharma's continued expansion within key industry sectors and geographic markets.

Prior to joining EvaluatePharma, Karle served as Vice President of Strategy and Development for global intelligence firm Thomson Reuters. There, he served on the executive leadership team and was responsible for defining and leading the corporate growth strategy for Thomson Reuters' intellectual property and science division, an $800M+ information and services business. Karle also led the restructuring of Thomson Reuters' pharmaceutical benchmarking business, CMR International, where he set strategy and defined new services to integrate with Thomson Reuters' life sciences business. Karle began his professional career as a Senior Associate at Booz Allen & Hamilton. Karle holds a Bachelor of Arts in business, economics and law from the European Business Programme in Münster, Germany and Hull, United Kingdom as well as a Master of Business Administration from Yale University's School of Management.

"Alexander brings a breadth of experience in driving corporate development for global intelligence firms within the life sciences. His expertise in driving successful operational growth for Thomson Reuters' science and healthcare businesses will be incredibly relevant," said Dr. Jonathan de Pass, EvaluatePharma CEO. "We are thrilled to welcome someone of his caliber to our executive leadership team."

About EvaluatePharma

Since 1996, EvaluatePharma has been the premier source for life science sector analysis, delivering exclusive, trusted commercial insight into industry performance through its proprietary platform. EvaluatePharma is staffed by a team of over 85 dedicated healthcare analysts employing rigorous methodologies to deliver the most-up-to-date commercial performance data available. An award winning editorial team of journalists writing under the EP Vantage name support EvaluatePharma's analysis.  The EvaluatePharma services enable the life science community to make sound business decisions about value and opportunity. For more information please visit http://www.EvaluatePharma.com.

Media Contacts:
EvaluatePharma
Christine Lindgren
+1-617-866-3906
christinel@EvaluatePharma.com

Chempetitive Group
Erik Clausen
+1-858-457-2436
rlear@chempetitive.com


'/>"/>
SOURCE EvaluatePharma Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. EvaluatePharma Names Debbie Paul CEO, Americas to Lead Growth in Key Region
2. AMRI Appoints Michael Nolan Vice President, Chief Financial Officer and Treasurer
3. Insmed Appoints Will Lewis as President and Chief Executive Officer
4. Circassia Appoints Dr Brett Haumann as Chief Medical Officer
5. Kinex Pharmaceuticals Appoints Mr. Patrick Gallagher Vice President of Business Development and Investor Relations
6. Islet Sciences Appoints Dr. Kevan Herold and Dr. Morton Printz to Scientific Advisory Board
7. Ameritox Appoints New CEO, Scott Walton
8. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
9. IRIDEX Appoints Chairman William M. Moore as Interim President & CEO
10. Landauer, Inc. Appoints Ronald Zilkowski To Vice President, Corporate Controller And Chief Accounting Officer
11. Henry Schein Appoints Carol Raphael to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 2016  Compass Diversified Holdings (NYSE: CODI ... of leading middle market businesses, announced today its consolidated ... 2016. First Quarter 2016 Highlights , ... or "Cash Flow") of $13.6 million for the first ... $15.0 million for the first quarter of 2016; ...
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Myeloid Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Myeloid Leukemia epidemiology, Acute Myeloid ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Dr. Benjamin Stong of Kalos Facial ... treatment. Dr. Stong is double board certified and the only facial plastic surgeon ... of hair loss. Non-surgical therapies such as stem cells can be used to provide ...
(Date:5/5/2016)... ... May 05, 2016 , ... In honor of National Nurses ... people all over the United States to thank a nurse who's made a difference ... donate $5 to the American Red Cross of San Diego/Imperial Counties (up to $10,000) ...
(Date:5/5/2016)... ... May 05, 2016 , ... Chronic stress can have a silent, ... can weaken the immune system and increase inflammation, both of which raise the risk ... adult congenital heart disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can ...
(Date:5/5/2016)... N.J. (PRWEB) , ... May 05, 2016 , ... ... patients with cancer, today announced a new collaboration with Imerman Angels to ... cancer anywhere in the world. , “Imerman Angels provides an emotional lifeline to patients ...
(Date:5/5/2016)... ... May 05, 2016 , ... Dermatologic surgeons performed nearly 10 million ... up 27 percent since 2012. , The results of the 2015 ASDS Survey on ... in skin cancer treatments and the growing popularity of soft-tissue fillers and body sculpting ...
Breaking Medicine News(10 mins):